StockNews.com Lowers Xencor (NASDAQ:XNCR) to Sell

StockNews.com cut shares of Xencor (NASDAQ:XNCR – Get Rating) from a hold rating to a sell rating in a report published on Monday.

Other research analysts have also issued reports about the stock. Piper Sandler decreased their target price on shares of Xencor from $66.00 to $42.00 and set an overweight rating on the stock in a research note on Monday, May 23rd. HC Wainwright cut their price target on shares of Xencor from $61.00 to $55.00 and set a buy rating for the company in a report on Thursday, February 24th. TheStreet upgraded shares of Xencor from a d+ rating to a c rating in a report on Wednesday, February 23rd. Finally, Cantor Fitzgerald restated an overweight rating on shares of Xencor in a report on Friday, April 1st. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Xencor presently has an average rating of Moderate Buy and a consensus price target of $52.33.

XNCR opened at $26.58 on Monday. The company’s 50 day simple moving average is $23.77 and its two-hundred day simple moving average is $29.75. Xencor has a 1-year low of $19.35 and a 1-year high of $43.61. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of 14.93 and a beta of 0.81.

Xencor (NASDAQ:XNCR – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $1.09. Xencor had a net margin of 33.28% and a return on equity of 15.74%. The business had revenue of $85.50 million for the quarter, compared to analyst estimates of $26.17 million. During the same period last year, the company posted ($0.04) EPS. The business’s revenue was up 152.2% on a year-over-year basis. On average, sell-side analysts forecast that Xencor will post -1.62 EPS for the current year.

A number of institutional investors have recently bought and sold shares of XNCR. Prospera Financial Services Inc acquired a new stake in Xencor in the 1st quarter valued at approximately $28,000. Point72 Hong Kong Ltd acquired a new stake in Xencor in the 4th quarter valued at approximately $41,000. Lazard Asset Management LLC increased its holdings in Xencor by 203.0% in the 1st quarter. Lazard Asset Management LLC now owns 4,485 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 3,005 shares during the last quarter. American Century Companies Inc. acquired a new stake in Xencor in the 4th quarter valued at approximately $201,000. Finally, Profund Advisors LLC acquired a new stake in Xencor in the 4th quarter valued at approximately $213,000. Hedge funds and other institutional investors own 98.43% of the company’s stock.

Xencor Company Profile (Get Rating)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

See Also